**Name of journal:** ***World Journal of*** ***Gastroenterology***

**ESPS Manuscript NO: 30280**

**Manuscript Type: REVIEW**

**Maximizing the endosonography: The role of contrast harmonics, elastography and confocal endomicroscopy**

Seicean A *et al.* Contrast EUS, elastography and nCLE

Andrada Seicean, Ofelia Mosteanu, Radu Seicean

**Andrada Seicean, Ofelia Mosteanu, Radu Seicean,** Regional Institute of Gastroenterology and Hepatology Cluj-Napoca, University of Medicine and Pharmacy ”Iuliu Hatieganu”, 400162 Cluj-Napoca, Romania

**Andrada Seicean, Ofelia Mosteanu, Radu Seicean,** First Surgical Clinic Cluj-Napoca, University of Medicine and Pharmacy ”Iuliu Hatieganu”, 400162 Cluj-Napoca, Romania

**Author contribution:** Seicean A conceived and designed the study. Seicean A, Mosteanu O, Seicean R analyzed and interpreted the data, drafted the article, and gave their approval for the final version of the article to be published.

**Supported by** National Grant of the Romanian Education Ministry, No. PN-II-PT-PCCA.2O 1 3-4-1 1 O5/2014.

**Conflict-of-interest** **statement:** No potential conflicts of interest relevant to this article were reported.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Ofelia Mosteanu, MD, PhD,** Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, Regional Institute of Gastroenterology and Hepatology, Croitorilor Street 19-21, 400162 Cluj-Napoca, Romania. ofeliamosteanu@gmail.com

**Telephone**: +40-742-073020

**Fax**: +40-264-431758

**Received:** September 23, 2016

**Peer-review started:** September 24, 2016

**First decision:** October 20, 2016

**Revised:** November 17, 2016

**Accepted:** December 8, 2016

**Article in press:**

**Published online:**

**Abstract**

New technologies in endoscopic ultrasound (EUS) evaluation have been developed because of the need to improve the EUS and EUS-fine needle aspiration (EUS-FNA) diagnostic rate. This paper reviews the principle, indications, main literature results, limitations and future expectations for each of the methods presented. Contrast-enhanced harmonic EUS uses a low mechanical index and highlights slow-flow vascularization. This technique is useful for differentiating solid and cystic pancreatic lesions and assessing biliary neoplasms, submucosal neoplasms and lymph nodes. It is also useful for the discrimination of pancreatic masses based on their qualitative patterns; however, the quantitative assessment needs to be improved. The detection of small solid lesions is better, and the EUS-FNA guidance needs further research. The differentiation of cystic lesions of the pancreas and the identification of the associated malignancy features represent the main indications. Elastography is used to assess tissue hardness based on the measurement of elasticity. Despite its low negative predictive value, elastography might rule out the diagnosis of malignancy for pancreatic masses. Needle confocal laser endomicroscopy offers useful information about cystic lesions of the pancreas and is still under evaluation for use with solid pancreatic lesions of lymph nodes.

**Key words:** Endosonography; Endosonography-fine needle aspiration; Contrast-enhanced; Harmonics; Elastography; Endomicroscopy; Pancreas; Lymph nodes; Cyst

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Contrast-enhanced harmonic endoscopic ultrasound, elastography and needle confocal laser endomicroscopy represent new, emerging technologies for improving the diagnosis obtained using endoscopic ultrasonography. This paper reviews the principle, indications, main literature results, limitations and future expectations for each of these methods, such as their use in the guidance or orientation of endoscopic ultrasound fine needle aspiration, molecular imaging and neurophysiology assessment in gastroenterology.

Seicean A, Mosteanu O, Seicean R. Maximizing the endosonography: The role of contrast harmonics, elastography and confocal endomicroscopy. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

New technologies in endosonography assessment are under development due to the limitations of standard endoscopic fine needle aspiration (EUS-FNA): the diagnostic accuracy for pancreatic masses is as high as 95% for cytology[1,2] and 86% for histology[3], the sensitivity for diagnosing lymph nodes is 90%[4], correct diagnosis is difficult for submucosal neoplasms[5],the differential diagnosis of pancreatic cysts is approximately 20%-30%[6], and the malignancy potential is sometimes challenging[7].

**CONTRAST HARMONICS ENDOSONOGRAPHY**

The use of Doppler contrast-enhanced EUS using a high mechanical index has been abandoned due to artifacts such as blooming, motion artifacts, poor spatial resolution, and low sensitivity to slow-flow structures[8].

The principle of contrast-enhanced harmonic imaging is to selectively depict signals from the microbubbles of ultrasound contrast agents, which resonate non-linearly when exposed to ultrasonic beams[9]. Background tissue signals are automatically subtracted, and only signals from the contrast agent are enhanced. The mechanical index (MI), which represents the ratio between the peak negative pressure amplitude and the square of the frequency, is related to the oscillation of the microbubbles. For an MI value of lower than 0.1, the bubble oscillation is linear, and no harmonics are produced. For an MI value of higher than 0.6, the microbubbles are destroyed. For this reason, an MI value of 0.14-0.4 is used during contrast-enhanced harmonics EUS (CH-EUS). These methods enable the dynamic observation of microvessels with slow flows that are not revealed by Doppler color, which differentiates perfused and non-perfused tissue; however, image resolution is reduced compared to that in B-mode images.

**EQUIPMENT AND CONTRAST SUBSTANCE**

CH-EUS can be performed using dynamic contrast harmonic imaging (dCHI) implemented onthe Hitachi platform and using the extended pure harmonic (ExpH) as technique implemented on Aloka platforms. The principle behind the first method is based on the emission of consecutive waves in phase inversion, followed by non-linear oscillation of the microbubbles[10]. The second system produces two transmitted pulses that consecutively reach the microbubble, yielding a phase shift between the two received waves[10]. The acoustic power used is low to avoid rapid destruction of the microbubbles (0.2-0.4). A suitable dynamic range that enables good visualization of small differences between vessels and the parenchyma and the focus under the target lesion should be fixed before the contrast injection starts.

Two major contrast substances have been used. Sonovue (Bracco Imaging, Milan, Italy) contains microbubbles of sulfur hexafluoride gas enclosed in a lipid shell. Its injection is followed by an arterial phase (the first 25-30 s after the injection) and a venous phase (30-45 s after the injection). Sonazoid (Daiichi-Sankyo, Tokyo, Japan), which is unavailable in Europe and comprises perfluorobutane in a lipid shell, is uptaken by Kupffer cells, conferring a longer duration than Sonovue.

**INDICATIONS FOR THE USE OF CH-EUS**

(1) Assessment of solid and cystic lesions of the pancreas; (2) characterization of submucosal neoplasms; (3) assessment of biliary neoplasms; and (4) assessment of lymph nodes

**SOLID PANCREATIC MASSES**

CH-EUS helps in mass differentiation,the differentiation between vascular (solid) and avascular (liquid/necrotic) components of the lesion, and the depiction of the dimensions and margins of the pancreatic mass, including its relationship with adjacent vessels.

***Mass differentiation***

CH-EUS examination has to report three descriptors[11,12], and the resulting pattern differs between lesions, enabling differentiation before the pathology result is available. Tables 1 and 2.

**Qualitative assessment:** Adenocarcinoma. Contrast uptake by small vessels reveals the low vascularity of these lesions. The hypoenhanced aspect has been reported as predictive for malignancy in several series of patients, with sensitivities of 84%-96%, specificities of 64%-94%, and accuracies 82%-92% (Table 3); further, two studies reported superior results compared to standard EUS[12,13].The pattern of contrast uptake can be inhomogenous when necrosis or intensive fibrosis is present, and fast wash-out is generally seen[12]. Some cases (4%-11% of cases) of isoenhanced/hyperenhanced adenocarcinoma aspect have been reported [14,15,16,17]. However, CH-EUS cannot yet replace EUS-FNA for the differentiation of solid masses[14,15,17,18] (Figure 1).

A meta-analysis of the diagnosis of adenocarcinoma published in 2012 proved that hypoenhancement has a global sensitivity of 94% and a specificity of 89%. However, the main bias of this study was the combination of Doppler and harmonic contrast EUS[19]. A second meta-analysis on contrast-enhanced ultrasound included a combination of endoscopic and transabdominal methods, and its results cannot be generalized for CH-EUS[20]. In a retrospective study of small pancreatic masses, adenocarcinoma was found in only 40%[21] of cases, and CH-EUS might be useful for the identification of such hypoenhanced lesions, which can be sent for surgery without EUS-FNA.

Tumor types other than adenocarcinoma, such as neuroendocrine tumors (NET), chronic pancreatitis, autoimmune pancreatitis, serous cystadenoma, and metastasis, are iso/hyperenhanced[12,14], with a sensitivity of 39%-86% and a specificity of 98%[12,15]. However, only 69-100% of NET are hyperenhanced[12,14,15]. An inhomogenous pattern in these tumor types corresponding to hemorrhage or necrosis is suggestive of malignancy[12,22] and can be seen in 15% of cases[22]. Few data are available about the usefulness of CH-EUS compared to standard EUS and were acquired in a very limited number of patients (*n* = 19) (Sn = 78.9%, Sp = 98%), providing a similar value as CT scanning when the small lesions were taken into account[15] (Figure 2).

Focal inflammatory mass may have a hypoechoic appearance in standard EUS and may exhibit diffuse iso/hyperenhancement using CH-EUS[15,16,23] with homogenous or inhomogenous content and fast wash-out. Sometimes these masses present as hypoenhanced lesions (9%-17%) because they exhibit different degrees of fibrosis[14,15,24]. The presence of calcifications is a confounding factor and should be avoided in the region of interest while analyzing contrast uptake. Only one study on solid pancreatic masses compared the low mechanical index of CH-EUS with the high mechanical index of contrast Doppler CEUS, and the second method was found to be superior. The main reason for this was the lack of contrast enhancement in patients with chronic pancreatitis, which was perhaps related to the machine settings; however, this cannot be assessed because the settings were not fully reported[24]. Autoimmune pancreatitis is usually homogenously isoenhanced[25] or hyperenhanced[14].

Cancer metastases are hyperenhanced (renal and thyroid carcinomas, lymphoma, and colon cancer)[14,26,27] or are hypoenhanced (colon cancer, sarcoma, and breast and ovarian cancer)[26,27]; melanoma is isoenhanced[26].

Interobserver agreement for solid pancreatic mass diagnosis showed modest results for the examinations using Sonovue (k = 0.46-0.66) and for the degree of enhancement[14,28]. The k coefficient was 0.94 for Sonazoid, a value that was perhaps related to the signal intensity and its duration. The effect of the endosonographer in CH-EUS was similar for experienced and non-experienced doctors[14,28], except in one study[29].

**Combined use of qualitative CH-EUS with EUS-FNA**: increased the sensitivity of differential diagnosis using Sonazoid from 92% to 100%, and the specificity was maintained at 92%[15,17]; these findings were similar to results obtained using Sonovue[18]. In addition, the hypoenhanced aspect obtained during CH-EUS proved to be useful in false negative cases of adenocarcinoma[17,18].

**Quantitative assessment:** Several attempts were done to quantify the image obtained during contrast injection. The dedicated software installed with the instruments is difficult to use because respiratory movements cannot be corrected by the software, and the time-intensity curve (TIC) has many artifacts.

The first study using quantitative assessment and harmonics was based on a hue histogram analysis, and the uptake ratio index between the mass and the surrounding parenchyma was 0.17, with a sensitivity of 80%[27] (Table 4). The post-processing analysis of the time-intensity curves using dedicated software showed that the inflammatory mass studied exhibited a dynamic enhancement pattern using CH-EUS that was similar to that obtained for the rest of the parenchyma, while an adenocarcinoma mass presented low contrast enhancement during the early arterial and late venous phases[24]. Two other studies showed that peak intensity and the rate of echo intensity decrease relative to the peak obtained at 1 minute were useful for differentiating malignant tumors[13,25].

A large multicentric study showed again that peak intensity and features related to the wash-in phase are good parameters for differentiating pancreatic masses, presenting a similar diagnostic rate to that obtained in studies using Sonazoid. However, the time-to-peak value revealed no significance[30]. Post-processing analysis of the TIC in a neural network showed even better diagnostic value, but further results are expected due to the extensive use of this method[30]. However, the software available for use with ultrasound machines awaits further refinement.

***Mass detection***

Mass detection is improved only in cases that are poorly seen using standard EUS, such as chronic pancreatitis or biliary stents[12]. CH-EUS is superior to CT for the detection of small tumors (Sn = 91.2%, Sp = 94.4%) but not for the detection of all tumors[15].

***Tumor staging***

Tumor staging appears to be better assessed using Sonazoid[31], in particular because the portal vein wall is more clearly seen[11]. No superiority in staging was observed when Sonovue was used[27], although vessel invasion and tumor size were more effectively seen in contrast-enhanced images[27].

***CH-EUS-FNA***

The orientation of the EUS-FNA after contrast injection in the hypoenhanced areas was first described by Kitano and then applied in 26% of cases with mixed adenocarcinoma to aid needle placement in the hypoenhanced area[14].

The guidance of the needle during the venous phase of contrast EUS was reported in some case reports and in three series[32]. The diagnostic value was similar to that of standard EUS-FNA in all three studies[27,33,34]. In one randomized control study, the first pass provided better cytology results than standard puncture and limited the number of passes[33]. Our results showed that a combination of two passes under contrast and two standard passes improved core histology-based diagnosis[27] (Figure 3). However, further larger multicenter studies are needed to establish the value of this method, which is safe, rapid, and entails minimal extra costs.

**CYSTIC LESIONS OF THE PANCREAS**

In cystic lesions of the pancreas (PCL), the cystic wall, septae and nodules are assessed for vascularization using the contrast-enhancing bubble movement[35],with the goal of obtaining a differential diagnosis of PCL and identifying malignancy risk features (vascularized wall nodules and the intracystic solid component).

***Differential diagnosis***

The CH-EUS degree and pattern of enhancement aids in the differentiation of PCL when used as an additional examination (Table 2). The method cannot replace EUS-FNA, except for with typical serous cystadenoma (SCA), because in 86% of cases, the aspect is hyperenhanced, with slow wash-out in 78% of cases[36]. Mucinous cystadenoma with neoplastic transformation presents thick septa and hyperenhanced mural nodules but cannot be differentiated from macrocystic SCA using CH-EUS[36]. Pancreatic pseudocysts have an avascular wall. However, in a series of 46 pseudocysts, three exhibited some wall vascularity[35]. These cysts can have a solid component without any contrast uptake during CH-EUS, thus avoiding EUS-FNA with a potential risk of infection[36]. Neuroendocrine tumors (NET) with a cystic aspect, despite the presence of a hyperenhanced rim, should be sampled by EUS-FNA to differentiate them from cystic adenocarcinoma.

The wall nodules of mucinous cystic neoplasms (MCNs) or intraductal papillary mucinous neoplasms (IPMNs) at risk of becoming malignant appear as hyper/isoechoic without a hyperechoic rim or are smooth edged, and the Doppler vascularity is seldom positive (2 of 14 cases were resected)[37]. CH-EUS is superior to EUS because it reveals small vessels by intense uptake of the contrast substance and differentiates the vessels from mucus or debris, which are not enhanced. Moreover, the CH-EUS may orientate/guide the EUS-FNA[36].

***Identification of risk features for malignancy***

CH-EUS differentiates unenhanced mucus or debris from the malignant nodules of MCNs or IPMNs, which are hyperenhanced, and fast wash-out has been reported in some retrospective studies (Table 5; Figure 4). The CH-EUS detection rate of malignant nodules (84-98%) was found to be superior to that of standard EUS and CT scan in three studies using Sonazoid[38,39,40]. The quantitative analysis of contrast uptake may add supplementary data for use in nodule assessment[41]. Several parameters have been described in a retrospective study using Sonazoid, such as the echo intensity change, echo intensity reduction rate and nodule/pancreatic parenchyma contrast ratio. The nodule size on CH-EUS was found to be predictive of malignancy (4 mm and 8 mm)[39,40]; however, another study found that size did not have predictive value[41]. Hyperenhancement of the solid component might orientate/guide EUS-FNA and help the operator to avoid puncturing debris, sludge and mucus plugs[36] (Figure 5).

**Interobserver agreement:** For cyst assessment was moderate for the uptake (k = 0.557), slight for the pattern (k = 0.083), and fair for the washout (k = 0.350)[28]. Considering mural nodules, interobserver agreement was excellent using Sonazoid as the contrast agent[40].

**Submucosal neoplasms:** Hyperenhancement of the submucosal neoplasm during contrast injection was considered suggestive of gastrointestinal stromal tumor (GIST) and is useful for differentiation from benign hypoenhanced lesions, such as lipoma and leiomyoma[42]. The consideration of irregular vessels as predictors of GIST malignancy has shown a sensitivity of 100% and a specificity of 63%[43]. Interobserver agreement was substantial (k = 0.63) for the uptake, slight for the pattern (k = 0.18), and fair for the washout (k = 0.39) (Figure 6).

**Biliary tumors:** Biliary polyps have been assessed using CH-EUS. Cholesterol polyps revealed heterogenous enhancement, and adenoma exhibited homogenous enhancement with a sensitivity and specificity of 75% and 66%, respectively[44]. However, the heterogenous aspect of a cholesterol polyp could be mistaken for adenoma due to the presence of microvessels with hyaline fibrosis[44].

Ampullary carcinoma and biliary tumors are hyperenhanced with fast wash-out[23,44]. The thick wall of the gallbladder makes it difficult to differentiate between malignant tumors and inflammatory modifications using standard EUS; however, CH-EUS improves the accuracy (94% *vs* 73%)[45]. The interobserver accuracy obtained when Sonazoid was used to examine the gallbladder wall was substantial (k = 0.77) [45].

**Lymph node assessment:** Round shape, sharp edge, and a short axis exceeding 8.3 mm are significantly associated with malignant cytology in LNs[46]. A retrospective study of CH-EUS use in LNs showed that 83% of malignant nodes presented a heterogenous pattern with distorted vessels and that a homogenous enhancement was suggestive of reactive lymph nodes[41]. The diagnostic value of CH-EUS for malignancy was characterized by a sensitivity, a specificity and an accuracy of 83%, 91% and 88% respectively[47]. Similar results have been reported for the characterization of intra-abdominal lesions of unknown origin[48]. The interobserver agreement obtained for LN assessment was excellent (k = 0.81)[47].

**Limitations:** (1) the duration of contrast enhancement is short, especially for Sonovue; (2)quantitative assessment is difficult due to respiratory movements; and (3) technical standardization is lacking.

**Future perspectives:** The contrast guidance of EUS-FNA could become a routine technique. Because CH-EUS has proven its role to show the change of size and tumor vascularity during chemotherapy for gastric cancers[49], it can be used also assess therapy in other digestive tumors.

***Elastography***

**Principle:** This technique assesses the hardness of the tissue by measuring its elasticity, similar to a virtual palpation. The compression of a target tissue by an echo-endoscopic probe produces a displacement of the tissue called “strain”, which correlates with the hardness of the structure.

**Technique:** It is essential to establish a large region of interest (ROI) that half comprises the lesion and half comprises the surrounding tissues such that the hardness of the lesion and that of the surrounding tissue can be compared. The probe of the echoendoscope, when upright, creates some pressure, and very small additional movements are important for obtaining the image.

Qualitative assessment is based on superimposing a colored image over the conventional gray-scale EUS image in a region of interest. The strain level of the hard tissue is colored in blue, and the soft tissue is colored in green. An elastic score has been proposed for the pancreas: homogenously hard, heterogenously hard, mixed, heterogenously soft, and homogenously soft[52].

Two semiquantitative approaches are included in the software and can be accessed during the EUS procedure. One approach calculates the hue histogram (strain histogram) as the ratio of the strain between two areas that are selected by the investigator, which are situated at the same distance from the transducer to obtain a similar compression by the probe[13]. The new generation of EUS elastography enables the operator to calculate the mean strain ratio (SR) within a selected area inside the ROI as the difference in elasticity between the targeted lesion and the surrounding tissue, yielding an objective numeric value. However, it is important to obtain a still image, and for this reason, multiple measurements are performed in each patient[53].

**Indications:** (1) differentiation of the pancreatic masses; (2)differentiation of the lymph nodes; and (3) assessment of fibrosis.

**Differentiation of pancreatic masses:** Normal pancreas tissue appears as soft tissue (green color) in E-EUS. A pancreatic mass, which is usually hypoechoic in standard EUS, appears as homogenously or inhomogenously green or blue, depending on tissue hardness[54-57].

Based on this qualitative assessment, the global sensitivity and specificity for pancreatic mass assessment were considered to be 100% and 67%, respectively[58]; however, a later multicentric European study found a sensitivity of 93.4% and a specificity of 66%, with a global accuracy of 85.4%[58]. Other studies obtained similar sensitivities and lower specificities for discriminating malignant pancreatic masses (Table 6). It was hoped that this examination could discriminate inflammatory changes from tumor involvement of the vessel wall[59],which has not yet been demonstrated (Figure 7).

Using the hue histogram, a value of 175 was found to be suggestive of malignancy[60,61]. However, artifacts related to the presence of surrounding structures with excessive or insufficient stiffness[61] are very important; therefore, the selection of appropriate regions of interest is of great importance.

Postprocessing analysis of the hue histogram using an artificial neural network enabled an optimal prediction of all types of pancreatic lesions and provided better results than hue histogram analysis[60,62]. However, the procedure is complex, and further studies on its practical applicability are warranted.

Multiple studies were performed to measure the mean SR and cut-off value for malignancy. No optimal cut-off value has yet been established for use in malignancy diagnosis (Table 6) due to the inter-observer variability of the method and the difficulty of standardizing the compression.

Two meta-analyses on the differentiation of malignant pancreatic tumors from inflammatory pancreatic masses, each including 13 studies with 1042 and 1044 patients, showed a sensitivity of 95% and a specificity of 67%-69%, with an AUC of 0.86-0.90[63,64]. A third meta-analysis included 7 studies and 752 patients, with a global sensitivity of 97%, a specificity of 76% and an AUC of 0.95[65]. This meta-analysis serves as a reminder that it is difficult to differentiate adenocarcinoma and neuroendocrine tumor, which are both hard lesions, using elastography[65]. A fourth meta-analysis found that the use of a color pattern for elastography EUS interpretation was associated with a sensitivity of 99% and a specificity of 69%-76%[65-67]; moreover, using a hue histogram, the sensitivity was 92% and the specificity was lower, 86%[66]. Both of the semiquantitative assessments evaluated by other meta-analyses showed a sensitivity of 96% and a specificity of 76%[67].

A comparison of B mode EUS, EUS-FNA and EUS elastography favored the standard EUS; the accuracies were 87%, 85% and 73%, respectively[68]. A combination of EUS-FNA with SR was not superior to EUS-FNA alone in a study involving 28 patients[69]. Due to the low negative value of LR (0.09), this method should be indicated to rule out a diagnosis of malignancy and to avoid unnecessary EUS-FNA [63].

**Limitations:** (1) The control of tissue compression (the degree of compression and the angulation) and motion artifacts determined by respiratory and heart movements is difficult[69-72]; (2)adjacent structures with very low or very high density should be avoided (the heart, major vessels). The interposition of cysts or dilated ducts should be avoided because these may impair the SR[73,74]; (3)the size and depth of the region of interest should be similar when SR is calculated[73]. This improves with the experience of the endosonographer, and modern equipment automatically selects the best still image that is representative of the mean SR of the lesion; (4)The negative predictive value remains low, at 60%-70%[69]; and (5) The procedure is poorly reproducible, and the coefficient of variance is greater than 0.3[69].

Interobserver variability is good in the case of experienced EUS elastography operators (k = 0.8) and is fair in the case of unexperienced EUS elastography operators (k = 0.24)[73]. Intraobserver variability was also good (k = 0.86-0.94)[59].

**Differentiation between benign and malignant lymph nodes:** The main problem in assessing lymph nodes is to determine when to apply EUS-FNA. Using EUS elastography, benign LNs appear homogenous and are colored green, whereas malignant LNs are colored blue[75]. The same color differentiation also proved efficient while applying elastography to endobronchial ultrasound[76]. Parts of LNs that appear blue can be targeted by the needle to prove the presence of micrometastasis.

The cut-off SR value for differentiating between malignant and benign LNs in 55 patients was considered to be 3.81[77]; a value of 7.5 was found in another group of 53 LNs[78]. Interobserver agreement was good to excellent, with a K value for ES of 0.58-0.84 and a value of 0.35 for the ES scoring system[79-81](Table 7).

A meta-analysis, including seven studies and 368 patients, revealed a sensitivity of 88% and a specificity of 85% using elastography EUS for differentiating between malignant and benign LNs[82].

Results concerning the superiority of elastography EUS over EUS are conflicting. The color pattern[79,83] and strain ratio were found to be of superior value to conventional EUS criteria[78]. However, these results were not sustained in another study that included a surgical pathology comparison[77].

**Assessment of pancreatic fibrosis:** The usefulness of elastography for assessing pancreatic fibrosis distal to a tumor and to differentiate chronic pancreatitis from healthy pancreas was previously proven[84,85]. Using a radial scope, an SR cut-off value of 2.25 yielded a diagnosis accuracy of 91% for chronic pancreatitis[1] and increased the EUS evaluation yield in 18% of cases. Autoimmune pancreatitis exhibits a blue pattern involving both mass-forming autoimmune pancreatitis and surrounding tissue[86].

A direct relationship was found between the SR and the probability of pancreatic exocrine insufficiency, as measured using the 13C-MTG breath test, and a probability of 87% was found in patients with an SR of higher than 4.5[87]. The results were similar for patients with calcifying and non-calcifying chronic pancreatitis[87]. No elastographic studies have compared this finding using radial and linear echoendoscopes.

**Other indications****:** Few cases of gastric submucosal tumors have been assessed using elastography[53,89]. A GIST may have a non-homogenous blue-green structure, and a typical lipoma is mostly soft, green and homogenous; however, differentiation between benign and malignant lesions using elastography EUS remains difficult.

Sessile rectal adenoma and adenocarcinoma were better differentiated using elastography compared to standard rectal endosonography, with an SR cut-off mean of 1.25, resulting in a sensitivity of 96% and a specificity of 86%; these results are superior to the use of EUS alone[90,91]. This could be important for the local resection of rectal tumors, but multiple studies confirming this indication are needed.

The discrimination between T2 and T3 tumors based on identifying “softer” inflammatory tissue and “harder“ tumor tissue has not yet been published.

Elastography was not found to be more useful compared to rectal EUS in patients with fecal incontinence, previously irradiated or not, where the sphincter appears as an interrupted inhomogenous thickened layer[53], or for the discrimination of Crohn strictures from adenocarcinoma.

Sclerosing primary cholangitis might have a hard or mixed type common bile duct wall compared to controls; this might be related to an extension of the fibrotic change of the wall[92].

**Future:** Site selection for EUS-FNA[59,65,93-95].

***Needle-based confocal endomicroscopy***

**Principle:** Standard confocal laser endomicroscopy (CLE) allows the real-time visualization of cellular and subcellular structures with up to 1000 times magnification and a penetration of 100 micrometers below the mucosal surface[96]. The studied tissue is illuminated with a low-power laser, and the fluorescence of light reflected from the tissue is subsequently detected through a pinhole[96]. The returned light is reflected by the same lens and reaches the detector of the confocal system. The illumination and detection systems are “confocal”, meaning that they are aligned in the same focal plane[96]. A contrast agent is administered intravenously (fluorescein) or topically (acriflavine and cresyl violet) to emphasize the cellular, subcellular and vasculature elements.

In clinical practice, two CLE systems are used: an endoscope-integrated CLE and a probe-based CLE (p-CLE), the latter being the widest system used for the assessment of colonic polyps, neoplastic lesions in inflammatory bowel diseases or Barrett's esophagus[99-102].

Needle-confocal endomicroscopy (nCLE) represents an improved version of CLE and is performed during EUS; the organs within or adjacent to the GI tract are assessed using a miniprobe, which is passed through an endoscopic needle. nCLE allows *in vivo,* real-time histological diagnosis, thus enhancing EUS performance, mainly in the setting of pancreatic and lymph node lesions[103]. Inconclusive diagnostic procedures can be decreased using this technique, termed “optical needle biopsy”[95].

**Technique:** The system comprises an AQ-Flex 19 miniprobe, which is inserted through a 19-gauge EUS needle while a fluorescence contrast agent (acriflavine, fluorescein) provides tissue architecture imaging, similar to standard histological examination (depth 40-70 mm, field of view 325 microns, lateral resolution 3.5 mm).

**Indications:** (1)cystic lesions of the pancreas larger than 1 cm; and (2) solid pancreatic masses and lymph node nCLE remain under evaluation.

**PCL:** The management of cystic lesions is currently suboptimal mainly due to a lack of accuracy in discriminating among different types of pancreatic cystic lesions.

The nCLE patterns for pancreatic cystic lesions were recently published [96,102,103] and provide a global accuracy for diagnosis ranging from 46 to 90%[102-106], and studies have underlined the importance of nCLE acting as an optical needle biopsy[93] (Table 8). Serous cystadenomas presents a superficial vascular network, which can stop their follow-up[103] or avoid an unnecessary resection (reported as 60% in a multicentric study of 2622 patients[107]). Benign IPMNs appear as finger-like papillary projections with an epithelial border and a vascular core, while malignant IPMNs appear as dark clumps with fluorescent substance leakage due to tumor neo-vascularization[103].

The multicentric INSPECT study[108] showed that the accuracy of differentiating between different types of PCL using nCLE was 41.9%, which is greater than that obtained using a carcinoembryonic antigen (CEA) level > 192 ng/mL (28.6%) or cytology results (29.6%). Epithelial villous structures were found to be predictive of PCL with a specificity of 100%, but the sensitivity and negative predictive value were only 59% and 50%, respectively[108].

In the DETECT trial[107], nCLE was combined with cystoscopy using a SpyGlass fiberoptic probe in 18 patients with a high probability of having PCNs. Cystoscopy and nCLE were reported to have sensitivities of 90% and 80%, respectively; the combination of the two methods reached a sensitivity of 100% for the clinical diagnosis of mucinous cysts. In addition, both cystoscopy and nCLE exhibited higher sensitivity and accuracy than CEA levels (33% and 61%, respectively) in the entire study population [109,110].

**Limitations**: (1) Inter-observer agreement is considered as globally low [106] and fair for MCN, moderate for IPMN, and very good for PC and SCA[102]; The operator learning curve of the technique influences the results obtained[103]; Sampling error is limited by the location and size of the cyst, the angulation of the needle, and the use of a transgastric or transduodenal approach; Incomplete evaluation – needle entry site, a solid mass inside the cyst; Better in combination with cystoscopy for cyst evaluation[109]; Complications of nCLE are seen in up to 3.29%-9% of cases such as pancreatitis or bleeding[102,106,107].

**Solid pancreatic lesions:** Few data are available for nCLE assessment in pancreatic solid lesions, and difficulties have been encountered, especially when using the transduodenal approach.

Normal pancreas has been described as having “an appearance of coffee beans corresponding to acinis”[110]. Adenocarcinoma has an aspect of dark cell aggregates and irregular vessels with the leakage of fluorescein[109], confirming previous studies[110,111]. Chronic pancreatitis presents as residual regular glandular pancreatic structures[109] and white fibrous bands [111,112]. Neuroendocrine tumors appear as black cell aggregates surrounded by vessels and fibrotic areas[109].

The sensitivity, specificity and accuracy of this technique were 77%, 100% and 85%, respectively, supporting the use of nCLE instead of repeating EUS-FNA after a previous inconclusive biopsy[109].

Another study used nCLE as optical guidance for EUS-FNA and found an accuracy rate of 90.9% with good inter-observer agreement (k=0.82). [111]

**Lymph nodes:** On nCLE, benign lymph nodes have a reticular background with lymphocytes[110]. Clusters of dark pleomorphic tumor cells are consistent with carcinoma features, while enlarged follicles are less convincing for malignancy[113]. Additionally, significant leakage of fluorescent dye due to tumor angiogenesis is suggestive of malignant nodes[110].

**Future:** Molecular imaging of the pancreas might be feasible using nCLE: pancreatic histology assessment after the use of a fluorescence-labeled anti-EGF-R antibody[114] has been reported. One study recently used nCLE for the visualization of the Meissner and Auerbach plexus after the submucosal injection of NeuroTrace[115], a new step in the assessment of functional and motility disorders of the gastrointestinal tract.

*In vitro* imaging of pancreatic carcinogenesis using nCLE combined with molecular markers, such as cathepsin E[96], has also been reported, with important future clinical implications for the monitoring of pancreatic ductal carcinoma.

Despite its high accuracy and the existence of several clinical applications, nCLE is still used only in research trials, probably due to a lack of standardization, availability and reimbursement in some countries, a lengthy physician learning curve and the broad range of histologic diagnoses. A recent study showed the benefit of using nCLE in cases of “diagnostic doubts”, impacting diagnosis and management in 40% of cases and the performance of target biopsies in 100% of cases[116].

**CONCLUSION**

The new derivative modalities described above represent a step forward in maximizing the results of endoscopic ultrasonography procedures. The complementary role of these techniques is becoming clearer, and elastography and harmonic contrast-enhanced EUS are suitable for routine use in the future. However, none of these techniques is yet able to replace EUS-FNA.

**REFERENCES**

1 **Puli SR**, Bechtold ML, Buxbaum JL, Eloubeidi MA. How good is endoscopic ultrasound-guided fine-needle aspiration in diagnosing the correct etiology for a solid pancreatic mass?: A meta-analysis and systematic review. *Pancreas* 2013; **42**: 20-26 [PMID: 23254913 DOI: 10.1097/MPA.0b013e3182546e79]

2 **Hewitt MJ**, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. *Gastrointest Endosc* 2012; **75**: 319-331 [PMID: 22248600 DOI: 10.1016/j.gie.2011.08.049]

3 **Bang JY**, Hawes R, Varadarajulu S. A meta-analysis comparing ProCore and standard fine-needle aspiration needles for endoscopic ultrasound-guided tissue acquisition. *Endoscopy* 2016; **48**: 339-349 [PMID: 26561917 DOI: 10.1055/s-0034-1393354]

4 **Micames CG**, McCrory DC, Pavey DA, Jowell PS, Gress FG. Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. *Chest* 2007; **131**: 539-548 [PMID: 17296659 DOI: 10.1378/chest.06-1437]

5 **Sekine M**, Imaoka H, Mizuno N, Hara K, Hijioka S, Niwa Y, Tajika M, Tanaka T, Ishihara M, Ito S, Misawa K, Ito Y, Shimizu Y, Yatabe Y, Ohnishi H, Yamao K. Clinical course of gastrointestinal stromal tumor diagnosed by endoscopic ultrasound-guided fine-needle aspiration. *Dig Endosc* 2015; **27**: 44-52 [PMID: 25059428 DOI: 10.1111/den.12333]

6 **Brugge WR**, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, del Castillo CF, Warshaw AL. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. *Gastroenterology* 2004; **126**: 1330-1336 [PMID: 15131794]

7 **Wang QX**, Xiao J, Orange M, Zhang H, Zhu YQ. EUS-Guided FNA for Diagnosis of Pancreatic Cystic Lesions: a Meta-Analysis. *Cell Physiol Biochem* 2015; **36**: 1197-1209 [PMID: 26138881 DOI: 10.1159/000430290]

8 **Dietrich CF**, Ignee A, Braden B, Barreiros AP, Ott M, Hocke M. Improved differentiation of pancreatic tumors using contrast-enhanced endoscopic ultrasound. *Clin Gastroenterol Hepatol* 2008; **6**: 590-597.e1 [PMID: 18455699 DOI: 10.1016/j.cgh.2008.02.030]

9 **Kitano M**, Kamata K, Imai H, Miyata T, Yasukawa S, Yanagisawa A, Kudo M. Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliary diseases. *Dig Endosc* 2015; **27** Suppl 1: 60-67 [PMID: 25639788 DOI: 10.1111/den.12454]

10 **Alvarez-Sánchez MV**, Napoléon B. Contrast-enhanced harmonic endoscopic ultrasound imaging: basic principles, present situation and future perspectives. *World J Gastroenterol* 2014; **20**: 15549-15563 [PMID: 25400439 DOI: 10.3748/wjg.v20.i42.15549]

11 **Kitano M**, Kudo M, Sakamoto H, Komaki T. Endoscopic ultrasonography and contrast-enhanced endoscopic ultrasonography. *Pancreatology* 2011; **11** Suppl 2: 28-33 [PMID: 21464584 DOI: 10.1159/000323493]

12 **Fusaroli P**, Spada A, Mancino MG, Caletti G. Contrast harmonic echo-endoscopic ultrasound improves accuracy in diagnosis of solid pancreatic masses. *Clin Gastroenterol Hepatol* 2010; **8**: 629-34.e1-2 [PMID: 20417721 DOI: 10.1016/j.cgh.2010.04.012]

13 **Hocke M**, Ignee A, Dietrich CF. Advanced endosonographic diagnostic tools for discrimination of focal chronic pancreatitis and pancreatic carcinoma--elastography, contrast enhanced high mechanical index (CEHMI) and low mechanical index (CELMI) endosonography in direct comparison. *Z Gastroenterol* 2012; **50**: 199-203 [PMID: 22298098 DOI: 10.1055/s-0031-1281824]

14 **Gincul R**, Palazzo M, Pujol B, Tubach F, Palazzo L, Lefort C, Fumex F, Lombard A, Ribeiro D, Fabre M, Hervieu V, Labadie M, Ponchon T, Napoléon B. Contrast-harmonic endoscopic ultrasound for the diagnosis of pancreatic adenocarcinoma: a prospective multicenter trial. *Endoscopy* 2014; **46**: 373-379 [PMID: 24532350 DOI: 10.1055/s-0034-1364969]

15 **Kitano M**, Kudo M, Yamao K, Takagi T, Sakamoto H, Komaki T, Kamata K, Imai H, Chiba Y, Okada M, Murakami T, Takeyama Y. Characterization of small solid tumors in the pancreas: the value of contrast-enhanced harmonic endoscopic ultrasonography. *Am J Gastroenterol* 2012; **107**: 303-310 [PMID: 22008892 DOI: 10.1038/ajg.2011.354]

16 **Lee TY**, Cheon YK, Shim CS. Clinical role of contrast-enhanced harmonic endoscopic ultrasound in differentiating solid lesions of the pancreas: a single-center experience in Korea. *Gut Liver* 2013; **7**: 599-604 [PMID: 24073319 DOI: 10.5009/gnl.2013.7.5.599]

17 **Park JS**, Kim HK, Bang BW, Kim SG, Jeong S, Lee DH. Effectiveness of contrast-enhanced harmonic endoscopic ultrasound for the evaluation of solid pancreatic masses. *World J Gastroenterol* 2014; **20**: 518-524 [PMID: 24574720 DOI: 10.3748/wjg.v20.i2.518]

18 **Napoleon B**, Alvarez-Sanchez MV, Gincoul R, Pujol B, Lefort C, Lepilliez V, Labadie M, Souquet JC, Queneau PE, Scoazec JY, Chayvialle JA, Ponchon T. Contrast-enhanced harmonic endoscopic ultrasound in solid lesions of the pancreas: results of a pilot study. *Endoscopy* 2010; **42**: 564-570 [PMID: 20593334 DOI: 10.1055/s-0030-1255537]

19 **Gong TT**, Hu DM, Zhu Q. Contrast-enhanced EUS for differential diagnosis of pancreatic mass lesions: a meta-analysis. *Gastrointest Endosc* 2012; **76**: 301-309 [PMID: 22703697 DOI: 10.1016/j.gie.2012.02.051]

20 **D'Onofrio M**, Biagioli E, Gerardi C, Canestrini S, Rulli E, Crosara S, De Robertis R, Floriani I. Diagnostic performance of contrast-enhanced ultrasound (CEUS) and contrast-enhanced endoscopic ultrasound (ECEUS) for the differentiation of pancreatic lesions: a systematic review and meta-analysis. *Ultraschall Med* 2014; **35**: 515-521 [PMID: 25226455 DOI: 10.1055/s-0034-1385068]

21 **Dietrich CF**, Sahai AV, D'Onofrio M, Will U, Arcidiacono PG, Petrone MC, Hocke M, Braden B, Burmester E, Möller K, Săftoiu A, Ignee A, Cui XW, Iordache S, Potthoff A, Iglesias-Garcia J, Fusaroli P, Dong Y, Jenssen C. Differential diagnosis of small solid pancreatic lesions. *Gastrointest Endosc* 2016; **84**: 933-940 [PMID: 27155592 DOI: 10.1016/j.gie.2016.04.034]

22 **Ishikawa T**, Itoh A, Kawashima H, Ohno E, Matsubara H, Itoh Y, Nakamura Y, Nakamura M, Miyahara R, Hayashi K, Ishigami M, Katano Y, Ohmiya N, Goto H, Hirooka Y. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors. *Gastrointest Endosc* 2010; **71**: 951-959 [PMID: 20438884 DOI: 10.1016/j.gie.2009.12.023]

23 **Ang TL**, Teo EK, Ang D, Kwek AB, Fock KM. A pilot study of contrast harmonic endosonography using DEFINITY™ in the evaluation of suspected pancreatic and peri-ampullary malignancies. *J Interv Gastroenterol* 2011; **1**: 160-165 [PMID: 22586529 DOI: 10.4161/jig.19958]

24 **Gheonea DI**, Streba CT, Ciurea T, Săftoiu A. Quantitative low mechanical index contrast-enhanced endoscopic ultrasound for the differential diagnosis of chronic pseudotumoral pancreatitis and pancreatic cancer. *BMC Gastroenterol* 2013; **13**: 2 [PMID: 23286918 DOI: 10.1186/1471-230X-13-2]

25 **Imazu H**, Kanazawa K, Mori N, Ikeda K, Kakutani H, Sumiyama K, Hino S, Ang TL, Omar S, Tajiri H. Novel quantitative perfusion analysis with contrast-enhanced harmonic EUS for differentiation of autoimmune pancreatitis from pancreatic carcinoma. *Scand J Gastroenterol* 2012; **47**: 853-860 [PMID: 22507131 DOI: 10.3109/00365521.2012.679686]

26 **Fusaroli P**, D'Ercole MC, De Giorgio R, Serrani M, Caletti G. Contrast harmonic endoscopic ultrasonography in the characterization of pancreatic metastases (with video). *Pancreas* 2014; **43**: 584-587 [PMID: 24713844 DOI: 10.1097/MPA.0000000000000081]

27 **Seicean A**, Badea R, Moldovan-Pop A, Vultur S, Botan EC, Zaharie T, Săftoiu A, Mocan T, Iancu C, Graur F, Sparchez Z, Seicean R. Harmonic Contrast-Enhanced Endoscopic Ultrasonography for the Guidance of Fine-Needle Aspiration in Solid Pancreatic Masses. *Ultraschall Med* 2015; Epub ahead of print [PMID: 26274382 DOI: 10.1055/s-0035-1553496]

28 **Fusaroli P**, Kypraios D, Mancino MG, Spada A, Benini MC, Bianchi M, Bocus P, De Angelis C, De Luca L, Fabbri C, Grillo A, Marzioni M, Reggio D, Togliani T, Zanarini S, Caletti G. Interobserver agreement in contrast harmonic endoscopic ultrasound. *J Gastroenterol Hepatol* 2012; **27**: 1063-1069 [PMID: 22414180 DOI: 10.1111/j.1440-1746.2012.07115.x]

29 **Soares JB**, Iglesias-Garcia J, Gonçalves B, Lindkvist B, Lariño-Noia J, Bastos P, Caetano AC, Ferreira A, Pimentel-Nunes P, Lopes L, Moutinho P, Dominguez-Muñoz JE. Interobserver agreement of contrast-enhanced harmonic endoscopic ultrasonography in the evaluation of solid pancreatic lesions. *Endosc Int Open* 2015; **3**: E205-E209 [PMID: 26171432 DOI: 10.1055/s-0034-1391415]

30 **Săftoiu A**, Vilmann P, Dietrich CF, Iglesias-Garcia J, Hocke M, Seicean A, Ignee A, Hassan H, Streba CT, Ioncică AM, Gheonea DI, Ciurea T. Quantitative contrast-enhanced harmonic EUS in differential diagnosis of focal pancreatic masses (with videos). *Gastrointest Endosc* 2015; **82**: 59-69 [PMID: 25792386 DOI: 10.1016/j.gie.2014.11.040]

31 **Imazu H**, Uchiyama Y, Matsunaga K, Ikeda K, Kakutani H, Sasaki Y, Sumiyama K, Ang TL, Omar S, Tajiri H. Contrast-enhanced harmonic EUS with novel ultrasonographic contrast (Sonazoid) in the preoperative T-staging for pancreaticobiliary malignancies. *Scand J Gastroenterol* 2010; **45**: 732-738 [PMID: 20205504 DOI: 10.3109/00365521003690269]

32 **Ueda K**, Yamashita Y, Itonaga M. Real-time contrast-enhanced endoscopic ultrasonography-guided fine-needle aspiration (with video). *Dig Endosc* 2013; **25**: 631 [PMID: 24112287 DOI: 10.1111/den.12165]

33 **Sugimoto M**, Takagi T, Hikichi T, Suzuki R, Watanabe K, Nakamura J, Kikuchi H, Konno N, Waragai Y, Watanabe H, Obara K, Ohira H. Conventional versus contrast-enhanced harmonic endoscopic ultrasonography-guided fine-needle aspiration for diagnosis of solid pancreatic lesions: A prospective randomized trial. *Pancreatology* 2015; **15**: 538-541 [PMID: 26145837 DOI: 10.1016/j.pan.2015.06.005]

34 **Hou X**, Jin Z, Xu C, Zhang M, Zhu J, Jiang F, Li Z. Contrast-enhanced harmonic endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of solid pancreatic lesions: a retrospective study. *PLoS One* 2015; **10**: e0121236 [PMID: 25793739 DOI: 10.1371/journal.pone.0121236]

35 **Hocke M**, Cui XW, Domagk D, Ignee A, Dietrich CF. Pancreatic cystic lesions: The value of contrast-enhanced endoscopic ultrasound to influence the clinical pathway. *Endosc Ultrasound* 2014; **3**: 123-130 [PMID: 24955342 DOI: 10.4103/2303-9027.131040]

36 **Fusaroli P**, Serrani M, De Giorgio R, D'Ercole MC, Ceroni L, Lisotti A, Caletti G. Contrast Harmonic-Endoscopic Ultrasound Is Useful to Identify Neoplastic Features of Pancreatic Cysts (With Videos). *Pancreas* 2016; **45**: 265-268 [PMID: 26474428 DOI: 10.1097/MPA.0000000000000441]

37 **Zhong N**, Zhang L, Takahashi N, Shalmiyev V, Canto MI, Clain JE, Deutsch JC, DeWitt J, Eloubeidi MA, Gleeson FC, Levy MJ, Mallery S, Raimondo M, Rajan E, Stevens T, Topazian M. Histologic and imaging features of mural nodules in mucinous pancreatic cysts. *Clin Gastroenterol Hepatol* 2012; **10**: 192-18, 192-18, [PMID: 21982970 DOI: 10.1016/j.cgh.2011.09.029]

38 **Yamashita Y**, Ueda K, Itonaga M, Yoshida T, Maeda H, Maekita T, Iguchi M, Tamai H, Ichinose M, Kato J. Usefulness of contrast-enhanced endoscopic sonography for discriminating mural nodules from mucous clots in intraductal papillary mucinous neoplasms: a single-center prospective study. *J Ultrasound Med* 2013; **32**: 61-68 [PMID: 23269711]

39 **Harima H**, Kaino S, Shinoda S, Kawano M, Suenaga S, Sakaida I. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography. *World J Gastroenterol* 2015; **21**: 6252-6260 [PMID: 26034360 DOI: 10.3748/wjg.v21.i20.6252]

40 **Kamata K**, Kitano M, Omoto S, Kadosaka K, Miyata T, Yamao K, Imai H, Sakamoto H, Harwani Y, Chikugo T, Chiba Y, Matsumoto I, Takeyama Y, Kudo M. Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cysts. *Endoscopy* 2016; **48**: 35-41 [PMID: 26605974 DOI: 10.1055/s-0034-1393564]

41 **Yamamoto N**, Kato H, Tomoda T, Matsumoto K, Sakakihara I, Noma Y, Horiguchi S, Harada R, Tsutsumi K, Hori K, Tanaka T, Okada H, de Yamamoto K. Contrast-enhanced harmonic endoscopic ultrasonography with time-intensity curve analysis for intraductal papillary mucinous neoplasms of the pancreas. *Endoscopy* 2016; **48**: 26-34 [PMID: 26561919 DOI: 10.1055/s-0034-1393563]

42 **Kannengiesser K**, Mahlke R, Petersen F, Peters A, Ross M, Kucharzik T, Maaser C. Contrast-enhanced harmonic endoscopic ultrasound is able to discriminate benign submucosal lesions from gastrointestinal stromal tumors. *Scand J Gastroenterol* 2012; **47**: 1515-1520 [PMID: 23148660 DOI: 10.3109/00365521.2012.729082]

43 **Sakamoto H**, Kitano M, Matsui S, Kamata K, Komaki T, Imai H, Dote K, Kudo M. Estimation of malignant potential of GI stromal tumors by contrast-enhanced harmonic EUS (with videos). *Gastrointest Endosc* 2011; **73**: 227-237 [PMID: 21295636 DOI: 10.1016/j.gie.2010.10.011]

44  **Park CH**, Chung MJ, Oh TG, Park JY, Bang S, Park SW, Kim H, Hwang HK, Lee WJ, Song SY. Differential diagnosis between gallbladder adenomas and cholesterol polyps on contrast-enhanced harmonic endoscopic ultrasonography. *Surg Endosc* 2013; **27**: 1414-1421 [PMID: 23233003 DOI: 10.1007/s00464-012-2620-x]

45 **Imazu H**, Mori N, Kanazawa K, Chiba M, Toyoizumi H, Torisu Y, Koyama S, Hino S, Ang TL, Tajiri H. Contrast-enhanced harmonic endoscopic ultrasonography in the differential diagnosis of gallbladder wall thickening. *Dig Dis Sci* 2014; **59**: 1909-1916 [PMID: 24664415 DOI: 10.1007/s10620-014-3115-5]

46 **Gill KR**, Ghabril MS, Jamil LH, Hasan MK, McNeil RB, Woodward TA, Raimondo M, Hoffman BJ, Hawes RH, Romagnuolo J, Wallace MB. Endosonographic features predictive of malignancy in mediastinal lymph nodes in patients with lung cancer. *Gastrointest Endosc* 2010; **72**: 265-271 [PMID: 20541192 DOI: 10.1016/j.gie.2010.02.037]

47 **Miyata T**, Kitano M, Omoto S, Kadosaka K, Kamata K, Imai H, Sakamoto H, Nisida N, Harwani Y, Murakami T, Takeyama Y, Chiba Y, Kudo M. Contrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreatobiliary carcinoma. *World J Gastroenterol* 2016; **22**: 3381-3391 [PMID: 27022220 DOI: 10.3748/wjg.v22.i12.3381]

48 **Xia Y**, Kitano M, Kudo M, Imai H, Kamata K, Sakamoto H, Komaki T. Characterization of intra-abdominal lesions of undetermined origin by contrast-enhanced harmonic EUS (with videos). *Gastrointest Endosc* 2010; **72**: 637-642 [PMID: 20646696 DOI: 10.1016/j.gie.2010.04.013]

49 **Matsui S**, Kudo M, Kitano M, Asakuma Y. Evaluation of the Response to Chemotherapy in Advanced Gastric Cancer by Contrast-Enhanced Harmonic EUS. *Hepatogastroenterology* 2015; **62**: 595-598 [PMID: 26897935]

50 **Matsubara H**, Itoh A, Kawashima H, Kasugai T, Ohno E, Ishikawa T, Itoh Y, Nakamura Y, Hiramatsu T, Nakamura M, Miyahara R, Ohmiya N, Ishigami M, Katano Y, Goto H, Hirooka Y. Dynamic quantitative evaluation of contrast-enhanced endoscopic ultrasonography in the diagnosis of pancreatic diseases. *Pancreas* 2011; **40**: 1073-1079 [PMID: 21633317 DOI: 10.1097/MPA.0b013e31821f57b7.PMID: 21633317]

51 **Seicean A**, Badea R, Stan-Iuga R, Mocan T, Gulei I, Pascu O. Quantitative contrast-enhanced harmonic endoscopic ultrasonography for the discrimination of solid pancreatic masses. *Ultraschall Med* 2010; **31**: 571-576 [PMID: 21080306 DOI: 10.1055/s-0029-1245833]

52 **Iglesias-Garcia J**, Domínguez-Muñoz JE, Castiñeira-Alvariño M, Luaces-Regueira M, Lariño-Noia J. Quantitative elastography associated with endoscopic ultrasound for the diagnosis of chronic pancreatitis. *Endoscopy* 2013; **45**: 781-788 [PMID: 24019131 DOI: 10.1055/s-0033-1344614]

53 **Dietrich CF**, Săftoiu A, Jenssen C. Real time elastography endoscopic ultrasound (RTE-EUS), a comprehensive review. *Eur J Radiol* 2014; **83**: 405-414 [PMID: 23643030 DOI: 10.1016/j.ejrad.2013.03.023]

54 **Havre RF**, Ødegaard S, Gilja OH, Nesje LB. Characterization of solid focal pancreatic lesions using endoscopic ultrasonography with real-time elastography. *Scand J Gastroenterol* 2014; **49**: 742-751 [PMID: 24713038 DOI: 10.3109/00365521.2014.905627]

55 **Hirche TO**, Ignee A, Barreiros AP, Schreiber-Dietrich D, Jungblut S, Ott M, Hirche H, Dietrich CF. Indications and limitations of endoscopic ultrasound elastography for evaluation of focal pancreatic lesions. *Endoscopy* 2008; **40**: 910-917 [PMID: 19009483 DOI: 10.1055/s-2008-1077726]

56 **Hu DM**, Gong TT, Zhu Q. Endoscopic ultrasound elastography for differential diagnosis of pancreatic masses: a meta-analysis. *Dig Dis Sci* 2013; **58**: 1125-1131 [PMID: 23306838 DOI: 10.1007/s10620-012-2428-5]

57 **Iglesias-Garcia J**, Larino-Noia J, Abdulkader I, Forteza J, Dominguez-Munoz JE. Quantitative endoscopic ultrasound elastography: an accurate method for the differentiation of solid pancreatic masses. *Gastroenterology* 2010; **139**: 1172-1180 [PMID: 20600020 DOI: 10.1053/j.gastro.2010.06.059]

58 **Giovannini M**, Hookey LC, Bories E, Pesenti C, Monges G, Delpero JR. Endoscopic ultrasound elastography: the first step towards virtual biopsy? Preliminary results in 49 patients. *Endoscopy* 2006; **38**: 344-348 [PMID: 16680632 DOI: 10.1055/s-2006-925158]

59 **Săftoiu A**, Vilmann P, Gorunescu F, Janssen J, Hocke M, Larsen M, Iglesias-Garcia J, Arcidiacono P, Will U, Giovannini M, Dietrich C, Havre R, Gheorghe C, McKay C, Gheonea DI, Ciurea T. Accuracy of endoscopic ultrasound elastography used for differential diagnosis of focal pancreatic masses: a multicenter study. *Endoscopy* 2011; **43**: 596-603 [PMID: 21437851 DOI: 10.1055/s-0030-1256314]

60 **Săftoiu A**, Vilmann P, Gorunescu F, Gheonea DI, Gorunescu M, Ciurea T, Popescu GL, Iordache A, Hassan H, Iordache S. Neural network analysis of dynamic sequences of EUS elastography used for the differential diagnosis of chronic pancreatitis and pancreatic cancer. *Gastrointest Endosc* 2008; **68**: 1086-1094 [PMID: 18656186 DOI: 10.1016/j.gie.2008.04.031]

61 **Săftoiu A**, Iordache SA, Gheonea DI, Popescu C, Maloş A, Gorunescu F, Ciurea T, Iordache A, Popescu GL, Manea CT. Combined contrast-enhanced power Doppler and real-time sonoelastography performed during EUS, used in the differential diagnosis of focal pancreatic masses (with videos). *Gastrointest Endosc* 2010; **72**: 739-747 [PMID: 20674916 DOI: 10.1016/j.gie.2010.02.056]

62 **Săftoiu A**, Vilmann P, Gorunescu F, Janssen J, Hocke M, Larsen M, Iglesias-Garcia J, Arcidiacono P, Will U, Giovannini M, Dietrich CF, Havre R, Gheorghe C, McKay C, Gheonea DI, Ciurea T. Efficacy of an artificial neural network-based approach to endoscopic ultrasound elastography in diagnosis of focal pancreatic masses. *Clin Gastroenterol Hepatol* 2012; **10**: 84-90.e1 [PMID: 21963957 DOI: 10.1016/j.cgh.2011.09.014]

63 **Pei Q**, Zou X, Zhang X, Chen M, Guo Y, Luo H. Diagnostic value of EUS elastography in differentiation of benign and malignant solid pancreatic masses: a meta-analysis. *Pancreatology* 2012; **12**: 402-408 [PMID: 23127527 DOI: 10.1016/j.pan.2012.07.013]

64 **Mei M**, Ni J, Liu D, Jin P, Sun L. EUS elastography for diagnosis of solid pancreatic masses: a meta-analysis. *Gastrointest Endosc* 2013; **77**: 578-589 [PMID: 23199646 DOI: 10.1016/j.gie.2012.09.035]

65 **Xu W**, Shi J, Li X, Zeng X, Lin Y. Endoscopic ultrasound elastography for differentiation of benign and malignant pancreatic masses: a systemic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2013; **25**: 218-224 [PMID: 23169307 DOI: 10.1097/MEG.0b013e32835a7f7c]

66 **Li X**, Xu W, Shi J, Lin Y, Zeng X. Endoscopic ultrasound elastography for differentiating between pancreatic adenocarcinoma and inflammatory masses: a meta-analysis. *World J Gastroenterol* 2013; **19**: 6284-6291 [PMID: 24115828 DOI: 10.3748/wjg.v19.i37.6284]

67 **Ying L**, Lin X, Xie ZL, Hu YP, Tang KF, Shi KQ. Clinical utility of endoscopic ultrasound elastography for identification of malignant pancreatic masses: a meta-analysis. *J Gastroenterol Hepatol* 2013; **28**: 1434-1443 [PMID: 23731128 DOI: 10.1111/jgh.12292]

68 **Mayerle J**, Beyer G, Simon P, Dickson EJ, Carter RC, Duthie F, Lerch MM, McKay CJ. Prospective cohort study comparing transient EUS guided elastography to EUS-FNA for the diagnosis of solid pancreatic mass lesions. *Pancreatology* 2016; **16**: 110-114 [PMID: 26602088 DOI: 10.1016/j.pan.2015.10.003]

69 Kongkam P, Lakananurak N, Navicharern P, Chantarojanasiri T, Aye K, Ridtitid W, Kritisin K, Angsuwatcharakon P, Aniwan S, Pittayanon R, Sampatanukul P, Treeprasertsuk S, Kullavanijaya P, Rerknimitr R. Combination of EUS-FNA and elastography (strain ratio) to exclude malignant solid pancreatic lesions: A prospective single-blinded study. J Gastroenterol Hepatol. 2015; 30: 1683-1689.

70 **Dawwas MF**, Taha H, Leeds JS, Nayar MK, Oppong KW. Diagnostic accuracy of quantitative EUS elastography for discriminating malignant from benign solid pancreatic masses: a prospective, single-center study. *Gastrointest Endosc* 2012; **76**: 953-961 [PMID: 22854060 DOI: 10.1016/j.gie.2012.05.034]

71 **Figueiredo FA**, da Silva PM, Monges G, Bories E, Pesenti C, Caillol F, Delpero JR, Giovannini M. Yield of Contrast-Enhanced Power Doppler Endoscopic Ultrasonography and Strain Ratio Obtained by EUS-Elastography in the Diagnosis of Focal Pancreatic Solid Lesions. *Endosc Ultrasound* 2012; **1**: 143-149 [PMID: 24949352 DOI: 10.7178/eus.03.005]

72 **Iglesias-Garcia J**, Larino-Noia J, Abdulkader I, Forteza J, Dominguez-Munoz JE. EUS elastography for the characterization of solid pancreatic masses. *Gastrointest Endosc* 2009; **70**: 1101-1108 [PMID: 19647248 DOI: 10.1016/j.gie.2009.05.011]

73 **Itokawa F**, Itoi T, Sofuni A, Kurihara T, Tsuchiya T, Ishii K, Tsuji S, Ikeuchi N, Umeda J, Tanaka R, Yokoyama N, Moriyasu F, Kasuya K, Nagao T, Kamisawa T, Tsuchida A. EUS elastography combined with the strain ratio of tissue elasticity for diagnosis of solid pancreatic masses. *J Gastroenterol* 2011; **46**: 843-853 [PMID: 21505859 DOI: 10.1007/s00535-011-0399-5]

74 **Lee TH**, Cho YD, Cha SW, Cho JY, Jang JY, Jeong SW, Choi HJ, Moon JH. Endoscopic ultrasound elastography for the pancreas in Korea: a preliminary single center study. *Clin Endosc* 2013; **46**: 172-177 [PMID: 23614128 DOI: 10.5946/ce.2013.46.2.172]

75 **Janssen J**, Schlörer E, Greiner L. EUS elastography of the pancreas: feasibility and pattern description of the normal pancreas, chronic pancreatitis, and focal pancreatic lesions. *Gastrointest Endosc* 2007; **65**: 971-978 [PMID: 17531630 DOI: 10.1016/j.gie.2006.12.057]

76 **Izumo T**, Sasada S, Chavez C, Matsumoto Y, Tsuchida T. Endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes. *Jpn J Clin Oncol* 2014; **44**: 956-962 [PMID: 25121724 DOI: 10.1093/jjco/hyu105]

77 **Larsen MH**, Fristrup CW, Mortensen MB. Intra- and interobserver agreement of endoscopic sonoelastography in the evaluation of lymph nodes. *Ultraschall Med* 2011; **32 Suppl 2**: E45-E50 [PMID: 22194049 DOI: 10.1055/s-0031-1273493]

78 **Paterson S**, Duthie F, Stanley AJ. Endoscopic ultrasound-guided elastography in the nodal staging of oesophageal cancer. *World J Gastroenterol* 2012; **18**: 889-895 [PMID: 22408347 DOI: 10.3748/wjg.v18.i9.889]

79 **Giovannini M**, Thomas B, Erwan B, Christian P, Fabrice C, Benjamin E, Geneviève M, Paolo A, Pierre D, Robert Y, Walter S, Hanz S, Carl S, Christoph D, Pierre E, Jean-Luc VL, Jacques D, Peter V, Andrian S. Endoscopic ultrasound elastography for evaluation of lymph nodes and pancreatic masses: a multicenter study. *World J Gastroenterol* 2009; **15**: 1587-1593 [PMID: 19340900]

80 **Janssen J**, Dietrich CF, Will U, Greiner L. Endosonographic elastography in the diagnosis of mediastinal lymph nodes. *Endoscopy* 2007; **39**: 952-957 [PMID: 18008203 DOI: 10.1055/s-2007-966946]

81 **Larsen MH**, Fristrup C, Hansen TP, Hovendal CP, Mortensen MB. Endoscopic ultrasound, endoscopic sonoelastography, and strain ratio evaluation of lymph nodes with histology as gold standard. *Endoscopy* 2012; **44**: 759-766 [PMID: 22752891 DOI: 10.1055/s-0032-1309817]

82 **Xu W**, Shi J, Zeng X, Li X, Xie WF, Guo J, Lin Y. EUS elastography for the differentiation of benign and malignant lymph nodes: a meta-analysis. *Gastrointest Endosc* 2011; **74**: 1001-109; quiz 1001-109; [PMID: 22032315 DOI: 10.1016/j.gie.2011.07.026]

83 **Knabe M**, Günter E, Ell C, Pech O. Can EUS elastography improve lymph node staging in esophageal cancer? *Surg Endosc* 2013; **27**: 1196-1202 [PMID: 23093233 DOI: 10.1007/s00464-012-2575-y]

84 **Itoh Y**, Itoh A, Kawashima H, Ohno E, Nakamura Y, Hiramatsu T, Sugimoto H, Sumi H, Hayashi D, Kuwahara T, Morishima T, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Katano Y, Ishigami M, Goto H, Hirooka Y. Quantitative analysis of diagnosing pancreatic fibrosis using EUS-elastography (comparison with surgical specimens). *J Gastroenterol* 2014; **49**: 1183-1192 [PMID: 24026103 DOI: 10.1007/s00535-013-0880-4]

85 **Janssen J**, Papavassiliou I. Effect of aging and diffuse chronic pancreatitis on pancreas elasticity evaluated using semiquantitative EUS elastography. *Ultraschall Med* 2014; **35**: 253-258 [PMID: 24327468 DOI: 10.1055/s-0033-1355767]

86 **Dietrich CF**, Hirche TO, Ott M, Ignee A. Real-time tissue elastography in the diagnosis of autoimmune pancreatitis. *Endoscopy* 2009; **41**: 718-720 [PMID: 19618344 DOI: 10.1055/s-0029-1214866]

87 **Dominguez-Muñoz JE**, Iglesias-Garcia J, Castiñeira Alvariño M, Luaces Regueira M, Lariño-Noia J. EUS elastography to predict pancreatic exocrine insufficiency in patients with chronic pancreatitis. *Gastrointest Endosc* 2015; **81**: 136-142 [PMID: 25088920 DOI: 10.1016/j.gie.2014.06.040]

88 **Allgayer H**, Ignee A, Zipse S, Crispin A, Dietrich CF. Endorectal ultrasound and real-time elastography in patients with fecal incontinence following anorectal surgery: a prospective comparison evaluating short- and long-term outcomes in irradiated and non-irradiated patients. *Z Gastroenterol* 2012; **50**: 1281-1286 [PMID: 23225555 DOI: 10.1055/s-0032-1313000]

89 **Jenssen C**, Dietrich CF. Endoscopic ultrasound of gastrointestinal subepithelial lesions. *Ultraschall Med* 2008; **29**: 236-56; quiz 257-64 [PMID: 18516768 DOI: 10.1055/s-2008-1027388]

90 **Waage JE**, Leh S, Røsler C, Pfeffer F, Bach SP, Havre RF, Haldorsen IS, Ødegaard S, Baatrup G. Endorectal ultrasonography, strain elastography and MRI differentiation of rectal adenomas and adenocarcinomas. *Colorectal Dis* 2015; **17**: 124-131 [PMID: 25407010 DOI: 10.1111/codi.12845]

91 **Azuma M**, Kusano C, Gotoda T. Diagnostic potential of endoscopic ultrasonography-elastography for gastric submucosal tumors. *Dig Endosc* 2015; **27** Suppl 1: 23 [PMID: 25556630 DOI: 10.1111/den.12429]

92 **Rustemovic N**, Cukovic-Cavka S, Opacic M, Petrovecki M, Hrstic I, Radic D, Ostojic R, Pulanic R, Vucelic B. Endoscopic ultrasound elastography as a method for screening the patients with suspected primary sclerosing cholangitis. *Eur J Gastroenterol Hepatol* 2010; **22**: 748-753 [PMID: 19494783 DOI: 10.1097/MEG.0b013e32832d489f]

93 **Rustemovic N**, Opacic D, Ostojic Z, Opacic M, Ledinsky I, Višijić A, Ravić KG, Iveković H, Markoš P. Comparison of elastography methods in patients with pancreatic masses. *Endosc Ultrasound* 2014; **3**: S4 [PMID: 26425528]

94 **Opačić D**, Rustemović N, Kalauz M, Markoš P, Ostojić Z, Majerović M, Ledinsky I, Višnjić A, Krznarić J, Opačić M. Endoscopic ultrasound elastography strain histograms in the evaluation of patients with pancreatic masses. *World J Gastroenterol* 2015; **21**: 4014-4019 [PMID: 25852289 DOI: 10.3748/wjg.v21.i13.4014]

95 **Săftoiu A**, Vilmann P, Ciurea T, Popescu GL, Iordache A, Hassan H, Gorunescu F, Iordache S. Dynamic analysis of EUS used for the differentiation of benign and malignant lymph nodes. *Gastrointest Endosc* 2007; **66**: 291-300 [PMID: 17643702 DOI: 10.1016/j.gie.2006.12.039]

96 **Chapman CG**, Siddiqui UD. New Scopes, New Accessories, New Stents for Interventional Endoscopic Ultrasound. *Clin Endosc* 2016; **49**: 41-46 [PMID: 26855923 DOI: 10.5946/ce.2016.49.1.41]

97 **Kuiper T**, van den Broek FJ, van Eeden S, Fockens P, Dekker E. Feasibility and accuracy of confocal endomicroscopy in comparison with narrow-band imaging and chromoendoscopy for the differentiation of colorectal lesions. *Am J Gastroenterol* 2012; **107**: 543-550 [PMID: 22433922 DOI: 10.1038/ajg.2012.14]

98 **Neumann H**, Vieth M, Atreya R, Grauer M, Siebler J, Bernatik T, Neurath MF, Mudter J. Assessment of Crohn's disease activity by confocal laser endomicroscopy. *Inflamm Bowel Dis* 2012; **18**: 2261-2269 [PMID: 22344873 DOI: 10.1002/ibd.22907]

99 **van den Broek FJ**, van Es JA, van Eeden S, Stokkers PC, Ponsioen CY, Reitsma JB, Fockens P, Dekker E. Pilot study of probe-based confocal laser endomicroscopy during colonoscopic surveillance of patients with longstanding ulcerative colitis. *Endoscopy* 2011; **43**: 116-122 [PMID: 21165821 DOI: 10.1055/s-0030-1255954]

100 **Sharma P**, Meining AR, Coron E, Lightdale CJ, Wolfsen HC, Bansal A, Bajbouj M, Galmiche JP, Abrams JA, Rastogi A, Gupta N, Michalek JE, Lauwers GY, Wallace MB. Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. *Gastrointest Endosc* 2011; **74**: 465-472 [PMID: 21741642 DOI: 10.1016/j.gie.2011.04.004]

101 **Bhutani MS**, Koduru P, Joshi V, Karstensen JG, Saftoiu A, Vilmann P, Giovannini M. EUS-Guided Needle-Based Confocal Laser Endomicroscopy: A Novel Technique With Emerging Applications. *Gastroenterol Hepatol (N Y)* 2015; **11**: 235-240 [PMID: 27099595]

102 **Napoleon B**, Lemaistre AI, Pujol B, Caillol F, Lucidarme D, Bourdariat R, Morellon-Mialhe B, Fumex F, Lefort C, Lepilliez V, Palazzo L, Monges G, Poizat F, Giovannini M. In vivo characterization of pancreatic cystic lesions by needle-based confocal laser endomicroscopy (nCLE): proposition of a comprehensive nCLE classification confirmed by an external retrospective evaluation. *Surg Endosc* 2016; **30**: 2603-2612 [PMID: 26428198 DOI: 10.1007/s00464-015-4510-5]

103 **Napoléon B**, Lemaistre AI, Pujol B, Caillol F, Lucidarme D, Bourdariat R, Morellon-Mialhe B, Fumex F, Lefort C, Lepilliez V, Palazzo L, Monges G, Filoche B, Giovannini M. A novel approach to the diagnosis of pancreatic serous cystadenoma: needle-based confocal laser endomicroscopy. *Endoscopy* 2015; **47**: 26-32 [PMID: 25325684 DOI: 10.1055/s-0034-1390693]

104 **Karia K**, Waxman I, Konda VJ, Gress FG, Sethi A, Siddiqui UD, Sharaiha RZ, Kedia P, Jamal-Kabani A, Gaidhane M, Kahaleh M. Needle-based confocal endomicroscopy for pancreatic cysts: the current agreement in interpretation. *Gastrointest Endosc* 2016; **83**: 924-927 [PMID: 26382051 DOI: 10.1016/j.gie.2015.08.080]

105 **Jais B**, Rebours V, Malleo G, Salvia R, Fontana M, Maggino L, Bassi C, Manfredi R, Moran R, Lennon AM, Zaheer A, Wolfgang C, Hruban R, Marchegiani G, Fernández Del Castillo C, Brugge W, Ha Y, Kim MH, Oh D, Hirai I, Kimura W, Jang JY, Kim SW, Jung W, Kang H, Song SY, Kang CM, Lee WJ, Crippa S, Falconi M, Gomatos I, Neoptolemos J, Milanetto AC, Sperti C, Ricci C, Casadei R, Bissolati M, Balzano G, Frigerio I, Girelli R, Delhaye M, Bernier B, Wang H, Jang KT, Song DH, Huggett MT, Oppong KW, Pererva L, Kopchak KV, Del Chiaro M, Segersvard R, Lee LS, Conwell D, Osvaldt A, Campos V, Aguero Garcete G, Napoleon B, Matsumoto I, Shinzeki M, Bolado F, Fernandez JM, Keane MG, Pereira SP, Acuna IA, Vaquero EC, Angiolini MR, Zerbi A, Tang J, Leong RW, Faccinetto A, Morana G, Petrone MC, Arcidiacono PG, Moon JH, Choi HJ, Gill RS, Pavey D, Ouaïssi M, Sastre B, Spandre M, De Angelis CG, Rios-Vives MA, Concepcion-Martin M, Ikeura T, Okazaki K, Frulloni L, Messina O, Lévy P. Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group on Cystic Tumors of the Pancreas). *Gut* 2016; **65**: 305-312 [PMID: 26045140 DOI: 10.1136/gutjnl-2015-309638]

106 **Konda VJ**, Meining A, Jamil LH, Giovannini M, Hwang JH, Wallace MB, Chang KJ, Siddiqui UD, Hart J, Lo SK, Saunders MD, Aslanian HR, Wroblewski K, Waxman I. A pilot study of in vivo identification of pancreatic cystic neoplasms with needle-based confocal laser endomicroscopy under endosonographic guidance. *Endoscopy* 2013; **45**: 1006-1013 [PMID: 24163192 DOI: 10.1055/s-0033-1344714]

107 **Nakai Y**, Iwashita T, Park DH, Samarasena JB, Lee JG, Chang KJ. Diagnosis of pancreatic cysts: EUS-guided, through-the-needle confocal laser-induced endomicroscopy and cystoscopy trial: DETECT study. *Gastrointest Endosc* 2015; **81**: 1204-1214 [PMID: 25634486 DOI: 10.1016/j.gie.2014.10.025]

108 **Ştefănescu D**, Pereira SP, Keane M, Săftoiu A. Needle-based confocal laser endomicroscopy in pancreatic cystic tumors assessment. *Rom J Morphol Embryol* 2015; **56**: 1263-1268 [PMID: 26743270]

109 **Giovannini M**, Caillol F, Monges G, Poizat F, Lemaistre AI, Pujol B, Lucidarme D, Palazzo L, Napoléon B. Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy in solid pancreatic masses. *Endoscopy* 2016; **48**: 892-898 [PMID: 27576181 DOI: 10.1055/s-0042-112573]

110 **Giovannini M**, Caillol F, Lemaistre A, Monges G, Napoleon B, Pujol B. Endoscopic ultrasound guided confocal microscopy: Atlas of cystic pancreatic lesions. *Endosc Ultrasound* 2014; **3**: S19-S21 [PMID: 26425522 DOI: 10.4103/2303-9027.129481]

111 **Kongkam P**, Pittayanon R, Sampatanukul P, Angsuwatcharakon P, Aniwan S, Prueksapanich P, Sriuranpong V, Navicharern P, Treeprasertsuk S, Kullavanijaya P, Rerknimitr R. Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy for diagnosis of solid pancreatic lesions (ENES): a pilot study. *Endosc Int Open* 2016; **4**: E17-E23 [PMID: 26793780 DOI: 10.1055/s-0034-1393183]

112 **Karstensen J**, Cartana T, Pia K, Saftoiu A, Vilmann P. Endoscopic ultrasound-guided needle confocal laser endomicroscopy in pancreatic masses. *Endosc Ultrasound* 2014; **3**: S2-S3 [PMID: 26425525]

113 **Benias PC**, D'Souza LS, Papafragkakis H, Kim J, Harshan M, Theise ND, Carr-Locke DL. Needle-based confocal endomicroscopy for evaluation of malignant lymph nodes - a feasibility study. *Endoscopy* 2016; **48**: 923-928 [PMID: 27434768 DOI: 10.1055/s-0042-109775]

114 **Nakai Y**, Shinoura S, Ahluwalia A, Tarnawski AS, Chang KJ. In vivo visualization of epidermal growth factor receptor and survivin expression in porcine pancreas using endoscopic ultrasound guided fine needle imaging with confocal laser-induced endomicroscopy. *J Physiol Pharmacol* 2012; **63**: 577-580 [PMID: 23388473]

115 **Samarasena JB**, Ahluwalia A, Shinoura S, Choi KD, Lee JG, Chang KJ, Tarnawski AS. In vivo imaging of porcine gastric enteric nervous system using confocal laser endomicroscopy & amp; molecular neuronal probe. *J Gastroenterol Hepatol* 2016; **31**: 802-807 [PMID: 26482711 DOI: 10.1111/jgh.13194]

116 **Robles-Medranda C**. Confocal endomicroscopy: Is it time to move on? *World J Gastrointest Endosc* 2016; **8**: 1-3 [PMID: 26788257 DOI: 10.4253/wjge.v8.i1.1]

**P-Reviewer:** Slomiany BL, Santoro GA, Tarnawski AS **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Romania

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Descriptors used in harmonic contrast-enhanced endoscopic ultrasound examination**

|  |  |  |  |
| --- | --- | --- | --- |
| Descriptors | Enhancement | Pattern of distribution | Wash-out |
| Hyper/iso/hypoenhancement | Homogenous/inhomogenous | Slow/Fast |
| Corresponding feature | Arteriolar density compared to the adjacent  normal parenchyma | Vascularity architecture | Velocity of the venous blood flow |
| Phase | Arterial | Arterial | Venous |

Arterial phase: 20 s to 30-45 s after injection; Venous phase: Later than 30-45 s after contrast injection.

**Table 2 Description of solid and cystic pancreatic lesions during harmonic contrast-enhanced endoscopic ultrasound examination**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Enhancement | Pattern of distribution | Wash-out |
| Solid pancreatic lesion | Adenocarcinoma | Hypoenhanced | homogenous/non-homogenous | Fast |
| NET | Hyperenhanced>Hypoenhanced | homogenous/non-homogenous | Slow> Fast |
| Chronic pancreatitis | Isoenhanced/Hyperenhanced>Hypoenhanced | homogenous/non-homogenous | Fast |
| Autoimmune pancreatitis | Isoenhanced/Hyperenhanced | homogenous/non-homogenous | Fast |
| Cystic pancreatic lesion | SCA | Hyperenhancement of the vascularized septae,  honeycomb aspect highlighted | homogenous | Slow |
| MCN | Hyperenhanced thick walls, thick septa and nodules are predictive for malignancy |  | Fast |
| Pseudocyst | avascular wall +  solid component without any contrast uptake |  | - |
| IPMN | Hyperenhanced septae and vascularized neoplastic nodules |  | Fast |
| NET cystic | Hyperenhanced wall and vascularized nodules |  | Slow |

NET: Neuroendocrine tumor; SCA: Serous cystadenoma; MCN: Mucinous cystic neoplasm; IPMN: Intraductal papillary mucinous neoplasm.

**Table 3 Results of CH-endoscopic ultrasound assessment for solid pancreatic masses in various studies**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study** | **Contrast agent** | **No. of patients** | **MI** | **Hypoenhancement as a sign of adenocarcinoma** | **EUS diagnostic rate** | **EUS-FNA diagnostic rate** |
| Napoleon *et al*[18] 2010 | Endoscopy | Sonovue | 35  PC-18  NET-9  CP-7 | 0.4 | Sn = 89%  Sp = 88%  PPV = 89%  NPV = 88%  Acc = 88.5% |  | Sn = 79%  Sp = 100%  PPV = 100%  NPV = 54%  Acc = 83% |
| Fusaroli  *et al*[12] 2010 | Prospective | Sonovue | 90  PC-51, NET-13, CP-13 | 0.36 radial  0.28 linear | Sn = 96%  Sp = 64%  Ac = 82% | Sn = 86%  Sp = 18%  Ac = 57% |  |
| Ang  *et al*[23] 2011 |  | Definity | 29 (PC-16, CP-4, Other-9) | 0.3 | Better detection of vascular invasion and tumor margins |  | - |
| Matsubara  *et al*[51] 2011 | Retrospective | Sonazoid | 91 | 0.2 | Sn = 87.5%  Sp = 77.8% | - | - |
| Hocke  *et al*[13] 2012 | Prospective | Sonovue | 58 | - | Sn = 84%  Sp = 76% | Sn = &3%  Sp = 61% | - |
| Kitano  *et al*[15] 2012 | Prospective | Sonazoid | 277 (PC-204, NET-19, CrP-46, Other-8) | 0.3 | Sn = 95%  Sp = 89% | - | Sn = 92%1  Sp = 100% |
| Lee  *et al*[16] 2013 | Prospective | Sonovue | 37 (PC-28, NET-5, CP-2) | - | Sn = 93%  Sp = 86%  PPV = 93%  NPV = 75%  Acc = 92% | - | - |
| Gincul  *et al*[14] 2014 | Prospective | Sonovue | 100  (PC-69,  NET-10, CP-13,  Other-8) | 0.4 | Sn = 96%  Sp = 94%  PPV = 94%  NPV = 97%  Acc = 91% |  | Sn = 95%  Sp = 93%  PPV = 100%  NPV = 100%  Acc = 86% |
| Park  *et al*[17] 2014 | Retrospective | Sonovue | 90 | - | Sn = 91.9%  Sp = 67.8% | - | Sn = 90%  Sp = 100% |
| Dietrich  *et al*[21] 2016 | Retrospective | Sonovue | 394  PC-146  NET-156 |  | Sn = 92% | - | \_ |

191 patients with resected lesions. MI: Mechanical index; PC: Pancreatic cancer; Cp: Chronic pancreatitis; NET: Neuroendocrine tumors.

**Table 4 Quantitative assessment studies for differentiating pancreatic masses**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study** | **Type of mass** | **Contrast agent** | **Type of echoendoscope** | **MI** | **Quantitative assessment** | **Features useful for differentiation** | **Diagnostic rate** |
| Seicean *et al*[52], 2010 | Prospective | PC-15  CP-12 | Sonovue | Radial | 0.36 | Hue histogram | Uptake index ratio | Sn = 80%  Sp = 91%  PPV = 92.8%  NPV = 78% |
| Matsubara *et al*[51], 2011[51] | Retrospective | PC-48  AIP-14  CP-13  NET-16 | Sonazoid | Linear | 0.2 | TIC | Echo intensity reduction rate relative to the peak at 1 minute | Sn = 87.5%  Sp = 88.9%  EUS+TIC  Sn = 95.8%  Sp = 92.6% |
| Gheonea *et al*[24], 2012 | Prospective | CP-19  PC-32 | Sonovue | Linear | 0.2 | Postprocessing TIC | Peak intensity intensity  TTP  AUC | Sn = 93.7%  Sp = 89.4% |
| Imazu *et al*[46], 2014 | Prospective | AIP-8  PC-22 | Sonazoid | Radial | 0.25-0.3 | TIC | Peak intensity  Maximum intensity gain | Sn = 100%  Sp = 100% |
| Saftoiu *et al*[30], 2015 | Prospective | PC-112  CP-55 | Sonovue | Linear  Radial | 0.1-0.3 | TIC | Peak intensity  Wash-in AUC  Wash-in rate  Wash-in perfusion index | Sn = 87.5%  Sp = 92.72% |

MI: Mechanical index; PC: Pancreatic cancer; CP: Chronic pancreatitis; NET: Neuroendocrine tumors; AIP: Autoimmune pancreatitis.

**Table 5 Contrast-enhanced endoscopic ultrasound for use in characterizing mural nodules in cystic pancreatic lesions**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study** | **MI** | **No. of patients** | **Type of cystic lesions** | **Contrast substance** | **Detection of mural nodules accuracy** | **Diagnosis of malignancy** | **Cut-off height for malignancy diagnosis(mm)** |
| Yamashita *et al*[38] 2013 | Retrospective | 0.36 | 17 | IPMN | Sonazoid | EUS-0  CT-71%  CH-EUS-94% |  |  |
| Hocke *et al*[35]  2014 | Retrospective | 0.02-0.18 | 125 | 1 MCN  6 MD-IPMN  16 BD-IPMN  103 others | Sonovue | Not defined | Not defined | - |
| Harima *et al*[39] 2015 | Retrospective | - | 50 | IPMN BD | Sonazoid | CT-92%  EUS-72%  CH-EUS-98% |  | 8.8 (AUROC = 0.93) |
| Kamata *et al*[40] 2015 | Retrospective | 0.3 | 70 | 6 MCN 42 BD-IPMNs  4 SCN  18 other | Sonazoid | EUS-73%  CH-EUS-84% | EUS-64  CH-EUS-84 | EUS-8 mm (AUROC = 0.84)  CH-EUS-4 mm (AUROC = 0.93) |
| Yamamoto *et al*[41] 2015 | Retrospective | 0.2 | 30 | 6/6/18  MD/BD/Mixt IPMN | Sonazoid |  | Echo intensity change-0.8  Echo intensity reduction  rate-0.9  Nodule/pancreatic parenchyma contrast ratio-0.89 | No effect on malignancy rate |

**Table 6 Efficiency of E-** **endoscopic ultrasound for solid pancreatic mass assessment**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study** | **Final diagnosis** | **No. of patients** | **E-EUS assessment** | **Main results** |
| Giovannini *et al*[60] 2006 | Prospective  Single center | Surgery  EUS-FNA | 24 | Color pattern | Sn = 100%  Sp = 67% |
| Janssen *et al*[77] 2007 | Prospective  Single center | Surgery  EUS-FNA | 73 | Color pattern | - |
| Saftoiu *et al*[62] 2008 | Prospective  Single center | Surgery  EUS-FNA | 43 | Hue histogram cut-off value=175 | Sn = 91%, Sp = 87%, PPV = 88%. NPV = 90%, Acc = 89% |
| Iglesias Garcia *et al*[74] 2009 | Prospective  Single center | Surgery  EUS-FNA | 130 | Color pattern | Sn = 100%, Sp = 85%, PPV = 90%, NPV= 100%, Acc = 94% |
| Giovannini *et al*[81] 2009 | Prospective  Multicenter | Surgery  EUS-FNA | 121 | Color pattern | Sn = 92%  Sp = 80% |
| Iglesias Garcias *et al*[59] 2010 | Prospective  Single center | Surgical  FNA | 86 | SR = 4.62 | Sn = 100%, Sp = 92% |
| Saftoiu *et al*[61]  2011 | Prospective Multicenter | Surgery  EUS-FNA | 258 | Hue histogram cut-off value = 175 | Sn = 93%, Sp = 66%, PPV = 92%, NPV = 68%, Acc = 85% |
| Itokawa *et al*[75] 2011 | Retrospective |  | 109 | SR=39.08 | - |
| Hocke *et al*[54] 2012 | Prospective  Single center | Surgical  EUS-FNA  Follow up | 58 | Color pattern | Sn = 94.7%  Sp = 33.4% |
| Figueiredo *et al*[73]  2012 | Prospective  Single center | Surgical  EUS-FNA  Follow up | 47 | SR = 8 | Sn = 90% Sp = 75% |
| Dawwas *et al*[72] 2012 | Prospective  Single center | Surgical  EUS-FNA | 111 | SR = 4.69 (AUC = 0.69)  Masks elasticity (AUC= 0.72) | Sn = 100%, Sp = 16.7%, PPV = 86%, NPV = 100%, Acc = 86%  Sn = 95%, Sp = 22%, PPV = 86%, NPV = 50%, Acc = 83% |
| Lee *et al*[76] 2013 | Retrospective | - | 15 | Color pattern  SR = 0.02% | - |
| Havre *et al*[56] 2014 | Prospective | Surgery  EUS-FNA  Follow-up | 48 | SR = 4.4 | Sn = 67%, Sp = 71% |
| Rustemovic *et al*[95] 2014 | Prospective  Single center | Surgery  EUS-FNA | 149 | SR = 7.59 | Sn = 100%  Sp = 45% |
| Kongkam *et al*[71] 2015 | Prospective  Single center | Surgery  EUS-FNA | 38 | SR=3.17 | Sn = 86%, Sp = 66% |
| Opacic *et al*[96] 2015 | Prospective  Single center | Surgery  EUS-FNA | 105 pancreatic mass  44 controls | Hue histogram | Sn = 98%, Sp = 50%, PPV = 92%, NPV = 100%, Ac = 69% |
| Mayerle *et al*[70] 2016 | Prospective  Single center | Surgery  EUS-FNA  Follow-up | 85 | SR = 24.82 or  10 | Sn = 77%, Sp = 65%  Sn = 96%, Sp = 43% |

E-EUS: Elastography endosonography; SR: Cut-off value of strain ratio; Sn: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; Acc: Accuracy.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **Type of study** | **Final diagnosis** | **No. of patients** | **E-EUS assessment** | **Main results** |
| Giovannini *et al*[60] 2006 | Prospective  Single center | EUS-FNA | 31 | Color pattern | Sn = 100%  Sp = 50% |
| Janssen  *et al*[77] 2007 | Prospective  Single center | EUS-FNA | 66 | Color pattern | Hard – Acc = 81-86%  Soft – Acc = 84-86% |
| Saftoiu  *et al*[97] 2007 | Prospective Single center | Surgery  EUS-FNA | 78 | Hue histogram | Sn = 85%  Sp = 91% |
| Giovannini  *et al*[81] 2009 | Prospective  Multicenter | Surgery  EUS-FNA | 101 | Color pattern | Sn = 91.8%  Sp = 82.5% |
| Larsen  *et al*[83] 2012 | Prospective Single center | Surgery | 56 | Color pattern | Sn = 55-59%  Sp = 82-85% |
| Paterson  *et al*[80] 2012 | Prospective  Single center | EUS-FNA | 53 | Strain ratio for malignancy = 7.5 | Sn = 83%, Sp = 96%, PPV = 95%, NPV = 86%, Acc = 90% |
| Knabe *et al*[85] 2013 | Prospective | EUS-FNA | 40 | Color pattern  Computed analysis | Sn = 100%  Sp = 64%  Computed analysis  Sn = 88.9%  Sp = 86.7% |


**Table 7 Efficiency of E-** **endoscopic ultrasound for LN assessment**

E-EUS: Elastographic endosonography; SR: cut-off value of the strain ratio; Sn: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value.


**Table 8 Needle confocal laser endosonography features of different cystic lesions of the pancreas**

|  |  |  |
| --- | --- | --- |
| **Type of lesion** | **nCLE features** | **Diagnostic rate, references** |
| SCA | a vascular network of the cystic wall | Sn = 69%, Sp = 100%, PPV = 100%, NPV = 82% [100] |
| MCN | a gray band delineated by a thin dark line. | Sn = 80%, Sp = 100% [103]  Sn = 67%, Sp = 96% [100] |
| IPMN | papillary projections: characterized by the alternation of vascular cores (white) and epithelial borders | Sn = 59%, Sp = 100% [102]  Sn = 80%, Sp = 92% [100] |
| Pseudocyst | inflammatory cells bright, gray and black particles | Sn = 43%, Sp = 100%, Acc = 87%[100] |
| Cystic NET | dark irregular clusters of compact cells + gray tissue of fibrovascular stroma | Sn = 67%, Sp = 96%, Acc = 90%[100] |


nCLE: Needle confocal laser endosonography; SCA: Serous cystadenoma; MCN: Mucinous cystic neoplasm; IPMN: Intraductal papillary mucinous neoplasm; NET: Neuroendocrine tumor; Sn: Sensitivity; Sp: Specificity; PPV: Positive predictive value; NPV: Negative predictive value; Acc: Accuracy.




**Figure 1 CH-** **endoscopic ultrasound of pancreatic adenocarcinoma.** Standard endoscopic ultrasound image (left) of a hypoenhanced lesion of the pancreatic body. The contrast-enhanced image (right) shows a hypoenhanced adenocarcinoma. The dilated pancreatic duct is seen upstream of the lesion.




**Figure 2 CH-** **endoscopic ultrasound of a neuroendocrine pancreatic tumor.** Standard endoscopic ultrasound image (left) of a hypoenhanced, well-delineated lesion of the head of the pancreas. The contrast image (right) shows a hyperenhanced lesion that is suggestive of a neuroendocrine tumor, as later proved by fine needle aspiration.




**Figure 3 CH-** **endoscopic ultrasound -FNA of solid pancreatic adenocarcinoma.** Standard EUS view of a hypoenhanced, inhomogenous adenocarcinoma of the head of the pancreas, showing anechoic parts suggestive of necrosis. The contrast image (right) highlights these avascular parts of the lesion, and the needle inside is clearly seen as avoiding them.




**Figure 4 CH-** **endoscopic ultrasound in mucinous cystadenomashowing features suggestive of malignancy.** Standard EUS image (left) of a macrocystic lesion of the pancreas with mural nodules and thin septae inside. The contrast image (right) shows vascularized mural nodules and no contrast uptake in some of the septae.



**Figure 5 CH-** **endoscopic ultrasound–FNA of a vascularized mural nodules within mucinous cystadenoma.** An endoscopic ultrasound-FNA needle during the puncture of one of the mural nodules is better seen on the contrast image (right).



**Figure 6 Contrast-enhanced harmonics endoscopic ultrasound of gastric gastrointestinal stromal tumor.** Endoscopic ultrasound standard image (right) of a gastric gastrointestinal stromal tumor of the muscularis propria. The contrast image (left) shows hyperenhancement of the lesion.



**Figure 7 Elastography of pancreatic neuroendocrine tumor - qualitative assessment.** Endoscopic ultrasound standard image (right) showing a well-delineated hypoenhanced lesion of the head of the pancreas. The elastography image (left) exhibits a blue pattern in this neuroendocrine tumor.